FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century

Frontiers in Oncology

Shun Huang¹  Fake Yang²  Jindan Li²  Conghui Yang²  Yongzhu Pu²  Rong Huang²  Yunchao Huang³  Yu Pu⁴  Long Chen⁴ 

[1] Department of Nuclear medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China;Department of PET/CT Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, China;Department of Thoracic Surgery I, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, China;Medical Imaging Key Laboratory of Sichuan Province, North Sichuan Medical College, Nanchong, China;

关键词: fibroblast-activating protein;    FAPI;    PET;    Neoplasms;    imaging;    18 F-FDG;   

DOI  :  10.3389/fonc.2022.854658

来源: DOAJ

【 摘 要 】

Fibroblast activation protein (FAP), a type II transmembrane serine protease, is highly expressed in more than 90% of epithelial tumors and is closely associated with various tumor invasion, metastasis, and prognosis. Using FAP as a target, various FAP inhibitors (FAPIs) have been developed, most of which have nanomolar levels of FAP affinity and high selectivity and are used for positron emission tomography (PET) imaging of different tumors. We have conducted a systematic review of the available data; summarized the biological principles of FAPIs for PET imaging, the synthesis model, and metabolic characteristics of the radiotracer; and compared the respective values of FAPIs and the current mainstream tracer 18F-Fludeoxyglucose (18F-FDG) in the clinical management of tumor and non-tumor lesions. Available research evidence indicates that FAPIs are a molecular imaging tool complementary to 18F-FDG and are expected to be the new molecule of the century with better imaging effects than 18F-FDG in a variety of cancers, including gastrointestinal tumors, liver tumors, breast tumors, and nasopharyngeal carcinoma.

【 授权许可】

Unknown